Halozyme Therapeutics (HALO) Operating Income Growth (1y) (2011 - 2026)
Halozyme Therapeutics (HALO) Operating Income Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 2,150.96% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 145.20% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Halozyme Therapeutics | 9.65 Bn | 9.33 Bn | 297.47 Mn | 30.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.37% |
| Dec 31, 2025 | -152.93% |
| Sep 30, 2025 | 33.53% |
| Jun 30, 2025 | 72.68% |
| Mar 31, 2025 | 48.14% |
| Dec 31, 2024 | 73.70% |
| Sep 30, 2024 | 84.87% |
| Jun 30, 2024 | 24.11% |
| Mar 31, 2024 | 77.58% |
| Dec 31, 2023 | 35.60% |
| Sep 30, 2023 | 5.99% |
| Jun 30, 2023 | 177.33% |
| Mar 31, 2023 | -28.90% |
| Dec 31, 2022 | 31.80% |
| Sep 30, 2022 | 10.20% |
| Jun 30, 2022 | -63.39% |
| Mar 31, 2022 | 49.15% |
| Dec 31, 2021 | -27.17% |
| Sep 30, 2021 | 87.56% |
| Jun 30, 2021 | 214.83% |